Clinical Trial: HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07131514) titled 'HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer' on Aug. 13.

Brief Summary: To evaluate the safety and efficacy of HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Pancreatic Cancer

Intervention: DRUG: HRS-4642+AG +Adebrelimab

HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab will be administrated per dose level in which the patients are assigned.

Recruitment Status: NO...